abacavir/lamivudine viatris abacavir (as sulfate)/lamivudine 600 mg/300 mg film-coated tablet blister pack
alphapharm pty ltd - lamivudine, quantity: 300 mg; abacavir sulfate, quantity: 702.78 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; silicified microcrystalline cellulose; purified talc; crospovidone; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - abacavir/lamivudine viatris tablets are a combination of two nucleoside analogues (abacavir and lamivudine). abacavir/lamivudine viatris is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.
abacavir/lamivudine 600/300 apotex abacavir 600mg (as sulfate) and lamivudine 300mg tablets bottle
arrotex pharmaceuticals pty ltd - lamivudine, quantity: 300 mg; abacavir sulfate, quantity: 702.76 mg (equivalent: abacavir, qty 600 mg) - tablet, film coated - excipient ingredients: hypromellose; titanium dioxide; sunset yellow fcf aluminium lake; macrogol 8000; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose - abacavir and lamivudine combination tablets are a combination of two nucleoside analogues (abacavir and lamivudine). ,abacavir and lamivudine combination tablets are indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.
lamivudine- lamivudine tablet, film coated
remedyrepack inc. - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 150 mg - lamivudine tablet is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (hiv-l) infection. limitation of use: the dosage of this product is for hiv-1and not for hbv. lamivudine tablets are contraindicated in patients with a previous hypersensitivity reaction to lamivudine. teratogenic effects pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lamivudine during pregnancy. physicians are encouraged to register patients by calling the antiretroviral pregnancy registry at 1-800-258-4263. risk summary available data from the antiretroviral pregnancy registry show no difference in the risk of overall major birth defects for lamivudine compared with the background rate for major birth defects of 2.7% in the us reference population of the metropolitan atlanta congenital defects program (macdp). lamivudine produced embryonic toxicity in rabbits at
lamivudine - lamivudine tablet, film coated
bryant ranch prepack - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 150 mg - lamivudine tablets are a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection. limitation of use: the dosage of this product is for hiv-1 and not for hbv. lamivudine tablets are contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., anaphylaxis) to any of the components of the product. pregnancy category c. there are no adequate and well-controlled studies of lamivudine in pregnant women. animal reproduction studies in rats and rabbits revealed no evidence of teratogenicity. increased early embryolethality occurred in rabbits at exposure levels similar to those in humans. lamivudine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. lamivudine pharmacokinetics were studied in pregnant women during 2 clinical studies conducted in south africa. the study assessed pharmacokinetics in: 16 women at 36 weeks gestation usin
abacavir/lamivudine 600/300 apotex abacavir 600mg (as sulfate) and lamivudine 300mg tablets blister pack
apotex pty ltd - abacavir sulfate,lamivudine -
lamivudine and zidovudine tablet, film coated
h.j. harkins company, inc. - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95), zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - lamivudine 150 mg - lamivudine and zidovudine tablets, a combination of two nucleoside analogues, are indicated in combination with other antiretrovirals for the treatment of hiv-1 infection. lamivudine and zidovudine tablets are contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., anaphylaxis, stevens-johnson syndrome) to any of the components of the product. fetal risk summary: there are no adequate and well-controlled studies of lamivudine and zidovudine in pregnant women. clinical trial data demonstrate that maternal zidovudine treatment during pregnancy reduces vertical transmission of hiv-1 infection to the fetus. animal reproduction studies performed with lamivudine and zidovudine showed increased embryotoxicity and fetal malformations (zidovudine), and increased embryolethality (lamivudine). lamivudine and zidovudine tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. antiretroviral pregnancy registry: to mon
lamivudine and zidovudine tablet, film coated
rebel distributors corp - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95), zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - lamivudine 150 mg - lamivudine and zidovudine tablets, a combination of two nucleoside analogues, are indicated in combination with other antiretrovirals for the treatment of hiv-1 infection. lamivudine and zidovudine tablets are contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., anaphylaxis, stevens-johnson syndrome) to any of the components of the product. fetal risk summary: there are no adequate and well-controlled studies of lamivudine and zidovudine in pregnant women. clinical trial data demonstrate that maternal zidovudine treatment during pregnancy reduces vertical transmission of hiv-1 infection to the fetus. animal reproduction studies performed with lamivudine and zidovudine showed increased embryotoxicity and fetal malformations (zidovudine), and increased embryolethality (lamivudine). lamivudine and zidovudine tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. antiretroviral pregnancy registry: to mon
lamivudine and zidovudine- lamivudine and zidovudine tablet
nucare pharmaceuticals,inc. - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95), zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - lamivudine 150 mg - lamivudine and zidovudine tablets, usp a combination of two nucleoside analogues, are indicated in combination with other antiretrovirals for the treatment of hiv-1 infection. lamivudine and zidovudine tablets, usp are contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., anaphylaxis, stevens-johnson syndrome) to any of the components of the product. pregnancy category c. fetal risk summary: there are no adequate and well-controlled studies of lamivudine and zidovudine in pregnant women. clinical trial data demonstrate that maternal zidovudine treatment during pregnancy reduces vertical transmission of hiv-1 infection to the fetus. animal reproduction studies performed with lamivudine and zidovudine showed increased embryotoxicity and fetal malformations (zidovudine), and increased embryolethality (lamivudine). lamivudine and zidovudine tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. antiretrovi
lamivudine and zidovudine tablet, film coated
exelan pharmaceuticals inc. - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95), zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - lamivudine 150 mg - lamivudine and zidovudine tablet, usp a combination of two nucleoside analogues, is indicated in combination with other antiretrovirals for the treatment of hiv-1 infection. lamivudine and zidovudine tablets are contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., anaphylaxis, stevens-johnson syndrome) to any of the components of the product. teratogenic effects: pregnancy category c. fetal risk summary: there are no adequate and well-controlled studies of lamivudine and zidovudine tablet in pregnant women. clinical trial data demonstrate that maternal zidovudine treatment during pregnancy reduces vertical transmission of hiv-1 infection to the fetus. animal reproduction studies performed with lamivudine and zidovudine showed increased embryotoxicity fetal malformations (zidovudine), and increased embryolethality (lamivudine). lamivudine and zidovudine tablet should be used during pregnancy only if the potential benefit justifies the potential ris
abacavir/lamivudine gh 600/300 abacavir (as hydrochloride) 600 mg and lamivudine 300 mg film-coated tablet blister pack
lupin australia pty limited - abacavir hydrochloride monohydrate,lamivudine -